|
1
|
Obermannová R, Alsina M, Cervantes A,
Leong T, Lordick F, Nilsson M, van Grieken NCT, Vogel A and Smyth
EC; ESMO Guidelines Committee. Electronic address, : simpleclinicalguidelines@esmo.org:
Oesophageal cancer: ESMO clinical practice guideline for diagnosis,
treatment and follow-up. Ann Oncol. 33:992–1004. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zeng H, Zhang F, Sun Y, Li S and Zhang W:
Treatment options for neoadjuvant strategies of esophageal squamous
cell carcinoma (Review). Mol Clin Oncol. 20:42024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chung CS, Lee YC, Wang CP, Ko JY, Wang WL,
Wu MS and Wang HP: Secondary prevention of esophageal squamous cell
carcinoma in areas where smoking, alcohol, and betel quid chewing
are prevalent. J Formos Med Assoc. 109:408–421. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Watanabe M, Otake R, Kozuki R, Toihata T,
Takahashi K, Okamura A and Imamura Y: Correction to: Recent
progress in multidisciplinary treatment for patients with
esophageal cancer. Surg Today. 50:4252020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Uhlenhopp DJ, Then EO, Sunkara T and
Gaduputi V: Epidemiology of esophageal cancer: Update in global
trends, etiology and risk factors. Clin J Gastroenterol.
13:1010–1021. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abnet CC, Arnold M and Wei WQ:
Epidemiology of esophageal squamous cell carcinoma.
Gastroenterology. 154:360–373. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chu LY, Peng YH, Weng XF, Xie JJ and Xu
YW: Blood-based biomarkers for early detection of esophageal
squamous cell carcinoma. World J Gastroenterol. 26:1708–1725. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu CQ, Ma YL, Qin Q, Wang PH, Luo Y, Xu
PF and Cui Y: Epidemiology of esophageal cancer in 2020 and
projections to 2030 and 2040. Thorac Cancer. 14:3–11. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lv H, He Z, Wang H, Du T and Pang Z:
Differential expression of miR-21 and miR-75 in esophageal
carcinoma patients and its clinical implication. Am J Transl Res.
8:3288–3298. 2016.PubMed/NCBI
|
|
11
|
Rui W, Li C, Da Q, Yue Y, Jing L, Ruirui
G, Youbin C, Lu T and Li B: Analysis of the influencing factors in
the long-term survival of esophageal cancer. Front Oncol.
13:12740142023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ren G, Wang Z, Tian Y, Li J, Ma Y, Zhou L,
Zhang C, Guo L, Diao H, Li L, et al: Targeted chemo-photodynamic
therapy toward esophageal cancer by GSH-sensitive theranostic
nanoplatform. Biomed Pharmacother. 153:1135062022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Del Valle-Morales D, Le P, Saviana M,
Romano G, Nigita G, Nana-Sinkam P and Acunzo M: The
Epitranscriptome in miRNAs: Crosstalk, detection, and function in
cancer. Genes (Basel). 13:12892022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi Y, Liu Z, Lin Q, Luo Q, Cen Y, Li J,
Fang X and Gong C: MiRNAs and cancer: Key link in diagnosis and
therapy. Genes (Basel). 12:12892021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zarrilli G, Galuppini F, Angerilli V,
Munari G, Sabbadin M, Lazzarin V, Nicolè L, Biancotti R and Fassan
M: miRNAs involved in esophageal carcinogenesis and miRNA-Related
therapeutic perspectives in esophageal carcinoma. Int J Mol Sci.
22:36402021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Inoue J and Inazawa J: Cancer-associated
miRNAs and their therapeutic potential. J Hum Genet. 66:937–945.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saliminejad K, Khorram Khorshid HR,
Soleymani Fard S and Ghaffari SH: An overview of microRNAs:
Biology, functions, therapeutics, and analysis methods. J Cell
Physiol. 234:5451–5465. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
He B, Zhao Z, Cai Q, Zhang Y, Zhang P, Shi
S, Xie H, Peng X, Yin W, Tao Y and Wang X: miRNA-based biomarkers,
therapies, and resistance in Cancer. Int J Biol Sci. 16:2628–2647.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ali Syeda Z, Langden SSS, Munkhzul C, Lee
M and Song SJ: Regulatory mechanism of MicroRNA expression in
cancer. Int J Mol Sci. 21:17232020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kousar K, Ahmad T, Abduh MS, Kanwal B,
Shah SS, Naseer F and Anjum S: miRNAs in regulation of tumor
microenvironment, chemotherapy resistance, immunotherapy modulation
and miRNA therapeutics in cancer. Int J Mol Sci. 23:138222022.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Popov A and Mandys V:
Senescence-associated miRNAs and their role in pancreatic cancer.
Pathol Oncol Res. 28:16101562022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chakrabortty A, Patton DJ, Smith BF and
Agarwal P: miRNAs: Potential as biomarkers and therapeutic targets
for cancer. Genes (Basel). 14:13752023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hussen BM, Hidayat HJ, Salihi A, Sabir DK,
Taheri M and Ghafouri-Fard S: MicroRNA: A signature for cancer
progression. Biomed Pharmacother. 138:1115282021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Haura EB, Turkson J and Jove R: Mechanisms
of disease: Insights into the emerging role of signal transducers
and activators of transcription in cancer. Nat Clin Pract Oncol.
2:315–324. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Furtek SL, Backos DS, Matheson CJ and
Reigan P: Strategies and approaches of targeting STAT3 for cancer
treatment. ACS Chem Biol. 11:308–318. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rahbar Farzam O, Najafi S, Amini M, Rahimi
Z, Dabbaghipour R, Zohdi O, Asemani Shahgoli G, Baradaran B and
Akbari B: Interplay of miRNAs and lncRNAs in STAT3 signaling
pathway in colorectal cancer progression. Cancer Cell Int.
24:162024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kamran MZ, Patil P and Gude RP: Role of
STAT3 in cancer metastasis and translational advances. Biomed Res
Int. 2013:4218212013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Z, Zhu S, Shen M, Liu J, Wang M, Li
C, Wang Y, Deng A and Mei Q: STAT3 is involved in esophageal
carcinogenesis through regulation of Oct-1. Carcinogenesis.
34:678–688. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yuan J, Zhang F and Niu R: Multiple
regulation pathways and pivotal biological functions of STAT3 in
cancer. Sci Rep. 5:176632015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Siveen KS, Sikka S, Surana R, Dai X, Zhang
J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3
signaling pathway in cancer: Role of synthetic and natural
inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI
|
|
31
|
Frank DA: STAT3 as a central mediator of
neoplastic cellular transformation. Cancer Lett. 251:199–210. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Germain D and Frank DA: Targeting the
cytoplasmic and nuclear functions of signal transducers and
activators of transcription 3 for cancer therapy. Clin Cancer Res.
13:5665–5669. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Turkson J and Jove R: STAT proteins: Novel
molecular targets for cancer drug discovery. Oncogene.
19:6613–6626. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cao Q, Li YY, He WF, Zhang ZZ, Zhou Q, Liu
X, Shen Y and Huang TT: Interplay between microRNAs and the STAT3
signaling pathway in human cancers. Physiol Genomics. 45:1206–1214.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu S, Li W, Liang L, Zhou Y and Li Y: The
regulatory relationship between transcription factor STAT3 and
noncoding RNA. Cell Mol Biol Lett. 29:42024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signalling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kohanbash G and Okada H: MicroRNAs and
STAT interplay. Semin Cancer Biol. 22:70–75. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xiang X, Ma HZ, Chen YQ, Zhang DZ, Ma SX,
Wang HJ, Liu DM, Yuan Y and Cai H: GM-CSF-miRNA-Jak2/Stat3
signaling mediates chemotherapy-induced cancer cell stemness in
gastric cancer. Front Pharmacol. 13:8553512022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sajjadi-Dokht M, Merza Mohamad TA,
Sulaiman Rahman H, Suliman Maashi M, Danshina S, Shomali N, Solali
S, Marofi F, Zeinalzadeh E, Akbari M, et al: MicroRNAs and
JAK/STAT3 signaling: A new promising therapeutic axis in blood
cancers. Genes Dis. 9:849–867. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ma RJ, Ma C, Hu K, Zhao MM, Zhang N and
Sun ZG: Molecular mechanism, regulation, and therapeutic targeting
of the STAT3 signaling pathway in esophageal cancer (Review). Int J
Oncol. 61:1052022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li Z, Qin X, Bian W, Li Y, Shan B, Yao Z
and Li S: Exosomal lncRNA ZFAS1 regulates esophageal squamous cell
carcinoma cell proliferation, invasion, migration and apoptosis via
microRNA-124/STAT3 axis. J Exp Clin Cancer Res. 38:4772019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cheng Y, Li Y, Nian Y, Liu D, Dai F and
Zhang J: STAT3 is involved in miR-124-mediated suppressive effects
on esophageal cancer cells. BMC Cancer. 15:3062015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhao Y, Ma K, Yang S, Zhang X, Wang F,
Zhang X, Liu H and Fan Q: MicroRNA-125a-5p enhances the sensitivity
of esophageal squamous cell carcinoma cells to cisplatin by
suppressing the activation of the STAT3 signaling pathway. Int J
Oncol. 53:644–658. 2018.PubMed/NCBI
|
|
44
|
Wang ZZ, Luo YR, Du J, Yu Y, Yang XZ, Cui
YJ and Jin XF: MiR-296-5p inhibits cell invasion and migration of
esophageal squamous cell carcinoma by downregulating STAT3
signaling. Eur Rev Med Pharmacol Sci. 23:5206–5214. 2019.PubMed/NCBI
|
|
45
|
Yuan RB, Zhang SH, He Y, Zhang XY and
Zhang YB: MiR-874-3p is an independent prognostic factor and
functions as an anti-oncomir in esophageal squamous cell carcinoma
via targeting STAT3. Eur Rev Med Pharmacol Sci. 22:7265–7273.
2018.PubMed/NCBI
|
|
46
|
Zang HL, Ji FJ, Ju HY and Tian XF:
Circular RNA AKT3 governs malignant behaviors of esophageal cancer
cells by sponging miR-17-5p. World J Gastroenterol. 27:240–254.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xu Z, Tie X, Li N, Yi Z, Shen F and Zhang
Y: Circular RNA hsa_circ_0000654 promotes esophageal squamous cell
carcinoma progression by regulating the miR-149-5p/IL-6/STAT3
pathway. IUBMB Life. 72:426–439. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Meng L, Wang F, Sun S, Zheng Y, Ding Z,
Sun Y, Li B, Meng Q and Xu M: MicroRNA-30b targets CBX3 and
regulates cell proliferation, apoptosis, and migration in
esophageal squamous cell carcinoma via the JAK2/STAT3 signaling
pathway. Int J Clin Exp Pathol. 10:11828–11837. 2017.PubMed/NCBI
|
|
49
|
Ke S, Fang M, Li R, Wang J and Lu J:
Downregulation of long noncoding RNA breast cancer anti-estrogen
resistance 4 inhibits cell proliferation, invasion, and migration
in esophageal squamous cell carcinoma by regulating the
microRNA-181c-5p/LIM and SH3 protein 1 axis. Bioengineered.
13:12998–13010. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chen Z, Hu X, Wu Y, Cong L, He X, Lu J,
Feng J and Liu D: Long non-coding RNA XIST promotes the development
of esophageal cancer by sponging miR-494 to regulate CDK6
expression. Biomed Pharmacother. 109:2228–2236. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yang H, Chen XW, Song XJ, Du HY and Si FC:
Baitouweng decoction suppresses growth of esophageal carcinoma
cells through miR-495-3p/BUB1/STAT3 axis. World J Gastrointest
Oncol. 16:3193–3210. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Han Y, Fan X, Fan L, Wu Y, Zhou Z, Wang G,
Guo L, Gao W, Chen Y and Gao Q: Liujunzi decoction exerts potent
antitumor activity in oesophageal squamous cell carcinoma by
inhibiting miR-34a/STAT3/IL-6R feedback loop, and modifies
antitumor immunity. Phytomedicine. 111:1546722023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang S, Wu G and Han Y, Li X, Feng X, Wang
H, Zhang L, Lin M, Cai Y and Han Y: miR-124 regulates
STAT3-mediated cell proliferation, migration and apoptosis in
bladder cancer. Oncol Lett. 16:5875–5881. 2018.PubMed/NCBI
|
|
54
|
Zhang J, Lu Y, Yue X, Li H, Luo X, Wang Y,
Wang K and Wan J: MiR-124 suppresses growth of human colorectal
cancer by inhibiting STAT3. PLoS One. 8:e703002013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lu Y, Yue X, Cui Y, Zhang J and Wang K:
MicroRNA-124 suppresses growth of human hepatocellular carcinoma by
targeting STAT3. Biochem Biophys Res Commun. 441:873–879. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chen M, Ye X, Wang R and Poon K: Research
progress of cancer stem cells and IL-6/STAT3 signaling pathway in
esophageal adenocarcinoma. Transl Cancer Res. 9:363–371. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lin H, Lian J, Xia L, Guan G and You J:
CBX3 promotes gastric cancer progression and affects factors
related to immunotherapeutic responses. Cancer Manag Res.
12:10113–10125. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yang K, Wang YL, Zhu Z, Cao XH, Liang MX,
Xu D, Fei YJ, Yang SY, Zhou HL and Tang JH: CBX3 promotes breast
cancer progression and high level of CBX3 predicts poor prognosis
in patients. Neoplasma. 70:71–81. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chen LY, Cheng CS, Qu C, Wang P, Chen H,
Meng ZQ and Chen Z: CBX3 promotes proliferation and regulates
glycolysis via suppressing FBP1 in pancreatic cancer. Biochem
Biophys Res Commun. 500:691–697. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhou C, Fan N, Liu F, Fang N, Plum PS,
Thieme R, Gockel I, Gromnitza S, Hillmer AM, Chon SH, et al:
Linking cancer stem cell plasticity to therapeutic
resistance-mechanism and novel therapeutic strategies in esophageal
cancer. Cells. 9:14812020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Huang B, Lang X and Li X: The role of
IL-6/JAK2/STAT3 signaling pathway in cancers. Front Oncol.
12:10231772022. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Mengie Ayele T, Tilahun Muche Z, Behaile
Teklemariam A, Bogale Kassie A and Chekol Abebe E: Role of
JAK2/STAT3 signaling pathway in the tumorigenesis, chemotherapy
resistance, and treatment of solid tumors: A systemic review. J
Inflamm Res. 15:1349–1364. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Fassl A, Geng Y and Sicinski P: CDK4 and
CDK6 kinases: From basic science to cancer therapy. Science.
375:eabc14952022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Jiang H, Guo Y, Huang K, Lu R, Peng X and
Lin S: MicroRNA-34a inhibits esophageal squamous cell carcinoma
progression by targeting E2F5. J Buon. 24:2514–2522.
2019.PubMed/NCBI
|
|
65
|
Ye Z, Xie T, Yan F, Wang L, Fang J, Wang
Z, Hu F, Wang F and Fu Z: MiR-34a reverses radiation resistance on
ECA-109 cells by inhibiting PI3K/AKT/mTOR signal pathway through
downregulating the expression of SIRT1. Int J Radiat Biol.
97:452–463. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Yang L, Song X, Zhu J, Li M, Ji Y, Wu F,
Chen Y, Cui X, Hu J, Wang L, et al: Tumor suppressor microRNA-34a
inhibits cell migration and invasion by targeting
MMP-2/MMP-9/FNDC3B in esophageal squamous cell carcinoma. Int J
Oncol. 51:378–388. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Nie J, Ge X, Geng Y, Cao H, Zhu W, Jiao Y,
Wu J, Zhou J and Cao J: miR-34a inhibits the migration and invasion
of esophageal squamous cell carcinoma by targeting Yin Yang-1.
Oncol Rep. 34:311–317. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Li M, Meng X and Li M: MiR-126 promotes
esophageal squamous cell carcinoma via inhibition of apoptosis and
autophagy. Aging (Albany NY). 12:12107–12118. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhang M, Tian H, Li R, Yan W and Xu R:
MicroRNA-4286 promotes esophageal carcinoma development by
targeting INPP4A to evoke the JAK2/STAT3 pathway activation.
Pharmazie. 73:342–348. 2018.PubMed/NCBI
|
|
70
|
Wang H, Peng D, Gan M, He Z and Kuang Y:
CPEB3 overexpression caused by miR-106b-5p inhibition inhibits
esophageal carcinoma in-vitro progression and metastasis.
Anticancer Drugs. 33:335–351. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Xu DD, Zhou PJ, Wang Y, Zhang L, Fu WY,
Ruan BB, Xu HP, Hu CZ, Tian L, Qin JH, et al: Reciprocal activation
between STAT3 and miR-181b regulates the proliferation of
esophageal cancer stem-like cells via the CYLD pathway. Mol Cancer.
15:402016. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zhang Y, Lu W, Chen Y, Lin Y, Yang X, Wang
H and Liu Z: The miR-19b-3p-MAP2K3-STAT3 feedback loop regulates
cell proliferation and invasion in esophageal squamous cell
carcinoma. Mol Oncol. 15:1566–1583. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Kong R, Ma Y, Feng J, Li S, Zhang W, Jiang
J, Zhang J, Qiao Z, Yang X and Zhou B: The crucial role of miR-126
on suppressing progression of esophageal cancer by targeting
VEGF-A. Cell Mol Biol Lett. 21:32016. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Li H, Meng F, Ma J, Yu Y, Hua X, Qin J and
Li Y: Insulin receptor substrate-1 and Golgi phosphoprotein 3 are
downstream targets of miR-126 in esophageal squamous cell
carcinoma. Oncol Rep. 32:1225–1233. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Nie ZC, Weng WH, Shang YS, Long Y, Li J,
Xu YT and Li Z: MicroRNA-126 is down-regulated in human esophageal
squamous cell carcinoma and inhibits the proliferation and
migration in EC109 cell via PI3K/AKT signaling pathway. Int J Clin
Exp Pathol. 8:4745–4754. 2015.PubMed/NCBI
|
|
76
|
Liu R, Gu J, Jiang P, Zheng Y, Liu X,
Jiang X, Huang E, Xiong S, Xu F, Liu G, et al: DNMT1-microRNA126
epigenetic circuit contributes to esophageal squamous cell
carcinoma growth via ADAM9-EGFR-AKT signaling. Clin Cancer Res.
21:854–863. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Gu JF, Liu SG, Pan Q, Qin F and Li YY:
Negative regulation of CDK6 expression by microRNA-126-5p and its
influence on the proliferation and invasion of esophageal cancer
cells. Anat Rec (Hoboken). 303:2811–2820. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Drahos J, Schwameis K, Orzolek LD, Hao H,
Birner P, Taylor PR, Pfeiffer RM, Schoppmann SF and Cook MB:
MicroRNA profiles of Barrett's esophagus and esophageal
adenocarcinoma: Differences in glandular non-native epithelium.
Cancer Epidemiol Biomarkers Prev. 25:429–437. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk
ML and Struhl K: STAT3 activation of miR-21 and miR-181b-1 via PTEN
and CYLD are part of the epigenetic switch linking inflammation to
cancer. Mol Cell. 39:493–506. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Zeng Q, Zhu Z, Song L and He Z:
Transferred by exosomes-derived MiR-19b-3p targets PTEN to regulate
esophageal cancer cell apoptosis, migration and invasion. Biosci
Rep. 40:BSR202018582020. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Chiam K, Mayne GC, Wang T, Watson DI,
Irvine TS, Bright T, Smith LT, Ball IA, Bowen JM, Keefe DM, et al:
Serum outperforms plasma in small extracellular vesicle microRNA
biomarker studies of adenocarcinoma of the esophagus. World J
Gastroenterol. 26:2570–2583. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Pandey P, Suyal G, Aprajita Pasbola K and
Sharma R: NGS-based profiling identifies miRNAs and pathways
dysregulated in cisplatin-resistant esophageal cancer cells. Funct
Integr Genomics. 23:1112023. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Sugimura K, Miyata H, Tanaka K, Hamano R,
Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori
M and Doki Y: Let-7 expression is a significant determinant of
response to chemotherapy through the regulation of IL-6/STAT3
pathway in esophageal squamous cell carcinoma. Clin Cancer Res.
18:5144–5153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Zhao Q, Huang L, Qin G, Qiao Y, Ren F,
Shen C, Wang S, Liu S, Lian J, Wang D, et al: Cancer-associated
fibroblasts induce monocytic myeloid-derived suppressor cell
generation via IL-6/exosomal miR-21-activated STAT3 signaling to
promote cisplatin resistance in esophageal squamous cell carcinoma.
Cancer Lett. 518:35–48. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Chen K, Wang X, Yang L and Chen Z: The
Anti-PD-1/PD-L1 immunotherapy for gastric esophageal cancer: A
systematic review and meta-analysis and literature review. Cancer
Control. 28:10732748219974302021. View Article : Google Scholar : PubMed/NCBI
|
